Summary of Concentra Group Holdings Parent, Inc. Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Revenue: $539.1 million, a 15.9% increase year-over-year from $465.0 million in Q4 2024. Excluding acquisitions, revenue was $493.8 million, up 6.2%.

Full Year 2025 Revenue: $2.2 billion, a 13.9% increase from $1.9 billion in 2024. Excluding acquisitions, revenue was $2.0 billion, a 6.4% increase.

Adjusted EBITDA: $95.3 million in Q4 2025 (up 22.9% from $77.5 million in Q4 2024) and $431.9 million for the full year (up 14.6%).

Adjusted Net Income: $36.1 million in Q4 2025, up from $22.2 million in Q4 2024. Full year adjusted net income was $176.0 million, compared to $168.5 million in 2024.

Adjusted EPS: $0.28 for Q4 2025, up from $0.17; $1.37 for the full year, down from $1.48 in 2024.

Visits: Total patient visits increased 9% in Q4 to over 51,000 per day, with a full-year increase of 7.7% to over 53,000 visits per day.

Cash Flow: Q4 operating cash flow was $118.7 million, up from $93.7 million in 2024. Free cash flow for the year was $197.8 million.

2Strategic Updates and Business Highlights

Acquisitions: Continued integration of Nova and Pivot, with strong synergies achieved. Plans for smaller bolt-on acquisitions remain active.

New Locations: Opened two de novo sites in Q4, totaling seven for 2025. A strong pipeline for 2026 includes additional sites across multiple states.

Market Position: Validation studies show Concentra's workers' compensation claims costs are 25% lower than non-Concentra providers, supporting their value proposition.

Technological Advancements: Enhanced sales technologies aimed at improving customer retention and engagement.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected between $2.25 billion and $2.35 billion.

Adjusted EBITDA Guidance: Projected between $450 million and $470 million.

CapEx Guidance: Anticipated between $70 million and $80 million.

Free Cash Flow Guidance: Targeted between $200 million and $225 million.

Leverage Target: Aiming for approximately 3.0x by the end of 2026.

Growth Assumptions: Expecting 3% rate growth and low single-digit visit growth, excluding acquisitions.

4Bad News, Challenges, or Points of Concern

Labor Market: The broader labor market showed anemic growth, which could impact customer base stability.

Increased Costs: Anticipated incremental separation costs associated with the transition from Select Medical could pressure margins in the short term.

Market Share Competition: While Concentra is gaining market share, the competitive landscape remains challenging, particularly in retaining smaller customers who may switch providers due to decision-maker turnover.

5Notable Q&A Insights

Weather and Respiratory Illness Impact: Management does not anticipate significant impacts from weather or respiratory illness on Q1 performance, as these factors are minimal relative to total visits.

New York Market Opportunity: Management is optimistic about potential changes in the New York workers' compensation fee schedule, which could facilitate entry into the market.

Labor Retention: Labor retention is improving, with turnover decreasing and fewer open positions, indicating a stable workforce.

De Novo Strategy: De novos contribute minimally to current growth rates, but management sees potential for increased openings in 2026. Overall, Concentra Group Holdings demonstrated strong financial performance in Q4 2025, with positive growth metrics and strategic initiatives aimed at enhancing market position and operational efficiency. However, challenges related to labor market conditions and cost management remain pertinent as they look to the future.